Publications
280 results found
Piccini P, Brooks DJ, Bjorklund A, et al., 1999, Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient, Nat Neurosci, Vol: 2, Pages: 1137-1140, ISSN: 1097-6256
Synaptic dopamine release from embryonic nigral transplants has been monitored in the striatum of a patient with Parkinson's disease using [11C]-raclopride positron emission tomography to measure dopamine D2 receptor occupancy by the endogenous transmitter. In this patient, who had received a transplant in the right putamen 10 years earlier, grafts had restored both basal and drug-induced dopamine release to normal levels. This was associated with sustained, marked clinical benefit and normalized levels of dopamine storage in the grafted putamen. Despite an ongoing disease process, grafted neurons can thus continue for a decade to store and release dopamine and give rise to substantial symptomatic relief.
Piccini P, Brooks DJ, 1999, Etiology of Parkinson's disease: contributions from 18F-DOPA positron emission tomography., Adv Neurol, Vol: 80, Pages: 227-231, ISSN: 0091-3952
Piccini P, Weeks RA, Brooks DJ, 1997, Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias, ANNALS OF NEUROLOGY, Vol: 42, Pages: 720-726, ISSN: 0364-5134
- Author Web Link
- Cite
- Citations: 148
Weeks RA, Cunningham VJ, Piccini P, et al., 1997, C-11-diprenorphine binding in Huntington's disease: A comparison of region of interest analysis with statistical parametric mapping, JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, Vol: 17, Pages: 943-949, ISSN: 0271-678X
- Author Web Link
- Cite
- Citations: 63
Weeks RA, CeballosBaumann A, Piccini P, et al., 1997, Cortical control of movement in Huntington's disease - A PET activation study, BRAIN, Vol: 120, Pages: 1569-1578, ISSN: 0006-8950
- Author Web Link
- Cite
- Citations: 64
Piccini P, Morrish PK, Turjanski N, et al., 1997, Dopaminergic function in familial Parkinson's disease: A clinical and F-18-dopa positron emission tomography study, ANNALS OF NEUROLOGY, Vol: 41, Pages: 222-229, ISSN: 0364-5134
- Author Web Link
- Cite
- Citations: 117
Weeks RA, Cunningham VJ, Piccini P, et al., 1997, <sup>11</sup>C-diprenorphine binding in Huntington's disease: A comparison of region of interest analysis with statistical parametric mapping, Journal of Cerebral Blood Flow and Metabolism, Vol: 17, Pages: 943-949, ISSN: 0271-678X
We compare region of interest (ROI) analytical approaches with statistical parametric mapping (SPM) of 11C-diprenorphine positron emission tomography findings in five patients with Huntington's disease (HD) and nine age-matched controls. The ROI were placed on caudate, putamen, and an occipital reference area. Ratios of striatal-occipital uptake from averaged static images centered at 60 minutes showed a mean 20% reduction in caudate (P = 0.034) and 15% reduction in putamen (P = 0.095) receptor binding in the HD patients. Dynamic data from caudate and putamen ROI, together with a plasma tracer input function, were analyzed using spectral analysis to give regional impulse response functions. Regional data at 60 minutes after impulse showed a mean 29% decrease in caudate (P = 0.006) and 23% decrease in putamen (P = 0.029) opioid binding in the HD cohort. Parametric images of tracer binding also were produced with spectral analysis on a voxel basis. The images of the unit impulse response function at 60 minutes showed a mean 31% decrease in caudate (P = 0.005) and a 26% decrease in putamen binding (P = 0.011) in HD. The voxel-based parametric images were transformed into standard stereotactic space, and a between-group comparison (patient versus controls) was performed with SPM. This approach revealed symmetrical decreases in caudate (peak 40% decrease, z score = 4.38) and putamen opioid binding (peak 24% decrease, z score = 4.686) with additional nonhypothesized changes in cingulate, prefrontal, and thalamic areas. The significance and precision of changes measured with spectral analysis applied to dynamic data sets were superior to ROI-based ratio analysis on static images. The SPM replicated the striatal reductions in opioid binding in HD and detected additional nonpredicted changes. This study suggests that SPM is a valid alternative to conventional ROI analytical approaches for determining binding changes with positron emission tomography and may have advantages o
Weeks RA, Piccini P, Harding AE, et al., 1996, Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease, ANNALS OF NEUROLOGY, Vol: 40, Pages: 49-54, ISSN: 0364-5134
- Author Web Link
- Cite
- Citations: 162
Lammertsma AA, Turjanski N, Hume SP, et al., 1996, Quantification of dopamine transporter studies using carbon-11 labelled RTI-121 and PET., JOURNAL OF NUCLEAR MEDICINE, Vol: 37, Pages: 426-426, ISSN: 0161-5505
Piccini P, Pavese N, Paoli C, et al., 1996, Are patients with Parkinson's disease more likely to wave periventricular hyperintensities develop? Reply, ARCHIVES OF NEUROLOGY, Vol: 53, Pages: 211-212, ISSN: 0003-9942
- Author Web Link
- Cite
- Citations: 1
Piccini P, Pavese N, Palombo C, et al., 1995, Transcranial Doppler Ultrasound in Migraine and Tension-Type Headache After Apomorphine Administration: Double-Blind Crossover Versus Placebo Study, Cephalalgia, Vol: 15, Pages: 399-403, ISSN: 0333-1024
PICCINI P, PAVESE N, PALOMBO C, et al., 1995, TRANSCRANIAL DOPPLER ULTRASOUND IN MIGRAINE AND TENSION-TYPE HEADACHE AFTER APOMORPHINE ADMINISTRATION - DOUBLE-BLIND CROSSOVER VERSUS PLACEBO STUDY, CEPHALALGIA, Vol: 15, Pages: 399-403, ISSN: 0333-1024
- Author Web Link
- Cite
- Citations: 19
PICCINI P, PAVESE N, CANAPICCHI R, et al., 1995, WHITE-MATTER HYPERINTENSITIES IN PARKINSONS-DISEASE - CLINICAL CORRELATIONS, ARCHIVES OF NEUROLOGY, Vol: 52, Pages: 191-194, ISSN: 0003-9942
- Author Web Link
- Cite
- Citations: 100
Piccini P, Turjanski N, Brooks DJ, 1995, PET studies of the striatal dopaminergic system in Parkinson's disease (PD), JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, Pages: 123-131, ISSN: 0303-6995
- Author Web Link
- Cite
- Citations: 11
Bonuccelli U, DAntonio P, DAvino C, et al., 1995, Dihydroergocryptine in the treatment of Parkinson's disease, 1st International Congress on Dopamine Agonists, Publisher: SPRINGER VERLAG, Pages: 239-245, ISSN: 0303-6995
- Author Web Link
- Cite
- Citations: 7
BONUCCELLI U, PICCINI P, DELDOTTO P, et al., 1993, APOMORPHINE TEST FOR DOPAMINERGIC RESPONSIVENESS - A DOSE ASSESSMENT STUDY, MOVEMENT DISORDERS, Vol: 8, Pages: 158-164, ISSN: 0885-3185
- Author Web Link
- Cite
- Citations: 34
Piccini P, Del Dotto P, Pardini C, et al., 1992, The dopaminergic responsiveness of sublingual apomorphine in Parkinson's disease, Pages: 238-241, ISSN: 0035-6344
Subcutaneous (s.c.) apomorphine has become, in recent years, the most popular dopaminergic agonist for the treatment of parkinsonian motor fluctuations, and has come to be used as a diagnostic test to discriminate idiopathic Parkinson's disease from parkinsonism. Recently, the use of a sublingual (s.l.) formulation has been reported to be effective in the treatment of motor fluctuations. In this study we have employed acute s.l. apomorphine administration as a tool for dopaminergic responsiveness in patients with parkinsonian features. We compared motor response to both s.c. and s.l. administration in 12 patients with Parkinson's disease. The magnitude of the motor response to s.c. and s.l. was similar. The onset of action of s.l. administration was delayed with respect to s.c. administration. Apomorphine side effects were similar with both routes, but were less severe after s.l. administration. Sublingual apomorphine test can be considered not only as effective as s.c. one, but also more advantageous.
Piccini P, Del Dotto P, Bertolucci A, et al., 1992, Subcutaneous and sublingual apomorphine test in Parkinson's disease, Pages: 527-533, ISSN: 0035-6336
The clinical diagnosis of Idiopathic Parkinson's Disease (IPD) remains difficult and is supported by a favourable response to levodopa, while failure to respond represents an exclusion criterion. In recent years subcutaneous (s.c.) apomorphine has come to be used as a tool in predicting levodopa responsiveness in parkinsonian syndromes. We administered apomorphine s.c. at dose of 10, 50 and 100 μg/kg against placebo, over two consecutive days, in 105 patients with parkinsonian features and evaluated motor parameters till to return to basal values. Subsequently, we compared the response to this test with the follow up response to levodopa therapy. 76 patients out of 105 showed a positive response to the apomorphine test and 29 had a negative one. After a 6 month follow up with levodopa/carbidopa therapy 82 patients improved, thus the apomorphine test was 87% predictive of the long-term response to levodopa. Recently, a sublingual (s.l.) formulation of apomorphine has been reported to reduce extrapyramidal symptoms after acute administration. We compared the motor response to apomorphine after 50 μg/kg s.c. and 25 mg s.l. administration. The onset of action of s.l. formulation was delayed with respect to s.c. one. The magnitude of the motor response to both routes was similar, but the apomorphine side effects were less frequent and severe after s.l. administration. These data allow us to affirm that the administration of both s.c. and s.l. formulations of apomorphine are useful as testes of dopaminergic responsiveness in parkinsonian syndromes.
BONUCCELLI U, DELDOTTO P, PICCINI P, et al., 1992, DEXTROMETHORPHAN AND PARKINSONISM, LANCET, Vol: 340, Pages: 53-53, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 46
BONUCCELLI U, PICCINI P, CORSINI GU, et al., 1992, APOMORPHINE IN MALIGNANT SYNDROME DUE TO LEVODOPA WITHDRAWAL, ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, Vol: 13, Pages: 169-170, ISSN: 0392-0461
- Author Web Link
- Cite
- Citations: 15
Bonuccelli U, Piccini P, Del Dotto P, et al., 1992, Apomorphine test in de novo Parkinson's disease., Funct Neurol, Vol: 7, Pages: 295-298, ISSN: 0393-5264
We administered apomorphine, a powerful dopaminergic agonist, subcutaneously to 25 untreated patients with parkinsonian features and evaluated motor response with the aim of discriminating idiopathic Parkinson's disease (IPD) from multiple system atrophy and progressive supranuclear palsy. The response to apomorphine was strongly predictive of responsiveness to subsequent levodopa follow-up and of the final diagnosis, made on the basis of both clinical and instrumental evaluation. Our data confirm that the apomorphine test is helpful in the differential diagnosis of IPD.
Ghelardoni F, De Iaco G, Ventavoli M, et al., 1991, [On the opportunity of treating with hyperbaric oxygenation (hyperbaric oxygen) for the prevention of post-interventional anoxic encephalopathy (delayed neurologic sequelae)]., Minerva Anestesiol, Vol: 57, Pages: 966-967, ISSN: 0375-9393
BONUCCELLI U, PICCINI P, DELDOTTO P, et al., 1991, NALOXONE PARTLY COUNTERACTS APOMORPHINE SIDE-EFFECTS, CLINICAL NEUROPHARMACOLOGY, Vol: 14, Pages: 442-449, ISSN: 0362-5664
- Author Web Link
- Cite
- Citations: 16
CAGNACCI A, MELIS GB, SOLDANI R, et al., 1991, ALTERED NEUROENDOCRINE REGULATION OF LUTEINIZING-HORMONE SECRETION IN POSTMENOPAUSAL WOMEN WITH PARKINSONS-DISEASE, NEUROENDOCRINOLOGY, Vol: 53, Pages: 549-555, ISSN: 0028-3835
- Author Web Link
- Cite
- Citations: 9
BONUCCELLI U, NUTI A, DELDOTTO P, et al., 1991, PLATELET PERIPHERAL BENZODIAZEPINE RECEPTORS ARE DECREASED IN PARKINSONS-DISEASE, LIFE SCIENCES, Vol: 48, Pages: 1185-1190, ISSN: 0024-3205
- Author Web Link
- Cite
- Citations: 17
Piccini P, Del Dotto P, Pardini C, et al., 1991, [Diurnal worsening in Parkinson patients treated with levodopa]., Pages: 219-224, ISSN: 0035-6344
Parkinson's disease (PD) patients show a good response to levodopa in the morning, and reduced duration or complete failure of response later in the day, but the pathophysiology of this phenomenon remains unclear. We evaluated motor performance hourly over a twelve-hour period in patients treated with levodopa/carbidopa (group A), with bromocriptine (group B), and in "de novo" patients (group C). At 8 am, 12 and 4 pm, group A patients received standard doses of levodopa/carbidopa, whereas patients of group B and C took, respectively, 5 mg bromocriptine and placebo. In "de novo" patients and in patients under bromocriptine we did not observe significant diurnal changes in motor score, whereas in patients under levodopa a progressive daytime worsening, which significantly correlated with progressive increase in 3-O-methyldopa plasma levels, was visible. These data seem to indicate a contributory role of pharmacokinetic or pharmacodynamic factors related to levodopa assumption, rather than to the underlying disease, in the afternoon worsening in PD.
BONUCCELLI U, PICCINI P, DELDOTTO P, et al., 1990, PLATELET MONOAMINE OXIDASE-B ACTIVITY IN PARKINSONIAN-PATIENTS, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 53, Pages: 854-855, ISSN: 0022-3050
- Author Web Link
- Cite
- Citations: 24
PICCINI P, NUTI A, PAOLETTI AM, et al., 1990, POSSIBLE INVOLVEMENT OF DOPAMINERGIC MECHANISMS IN THE ANTIMIGRAINE ACTION OF FLUNARIZINE, CEPHALALGIA, Vol: 10, Pages: 3-8, ISSN: 0333-1024
- Author Web Link
- Cite
- Citations: 25
Bonuccelli U, Nuti A, Rossi B, et al., 1990, Thyroid function and oral TRH in amyotrophic lateral sclerosis, New Trends in Clinical Neuropharmacology, Vol: 4, Pages: 33-42, ISSN: 0393-5345
Basal thyroid function, Thyrotropin (TSH) response to 200 μg of intravenous Thyrotropin Releasing Hormone (TRH) and thyroid autoantibodies have been studied in 20 patients with Amyotrophic Lateral Sclerosis (ALS). Moreover, the effectiveness of orally administered TRH (40 and 120 mg/day) was tested against placebo in 10 ALS patients. Basal thyroid and autoimmunity parameters all proved similar in patients and in controls. A blunted TSH response to TRH was observed in ALS patients compared to controls. Oral TRH was ineffective in modifying the clinical course of the disease, but muscular strength did not change significantly throughout the trial. These results indicate a functional derangement of hypotalamus-hypophisis-thyroid axis in ALS and the substantial lack of effect of oral TRH on the course of the disease.
BONUCCELLI U, PICCINI P, NAPOLITANO A, et al., 1990, REDUCED LUTEINIZING-HORMONE SECRETION IN WOMEN WITH PARKINSONS-DISEASE, JOURNAL OF NEURAL TRANSMISSION-PARKINSONS DISEASE AND DEMENTIA SECTION, Vol: 2, Pages: 225-231, ISSN: 0936-3076
- Author Web Link
- Cite
- Citations: 11
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.